Aquestive Therapeutics (AQST) has been on my radar since its IPO back in July of 2018. Unfortunately, the company has had a few regulatory setbacks with some partnered and secondary product candidates that have cut the share price. These setbacks have prevented me from buying into the stock on multiple occasions. However, the company’s major players are still in the game and the long-term outlook for the company remains intact.
I see the company’s developing CNS pipeline offering several products that can drive shareholder value. The company’s PharmFilm technology has a history of